Download the company's investor presentation and receive corporate updates.
Revive Therapeutics has significantly grown its psychedelics presence after acquiring Psilocin Pharma Corp. and partnering with PharmaTher Inc.
In-house IP portfolio covering psilocybin methods and compositions, as well as drug delivery systems, including convenient oral strips.
Raised $20 million in a bought deal offering to fund Phase I clinical trials for psilocybin for methamphetamine use disorder and other research.
Partnership with the University of Wisconsin to conduct clinical trials, as well as PharmaTher Inc. (CSE: PHRM) to develop novel treatments.
Targeting FDA designations, such as Orphan, Fast Track and Breakthrough Therapy Status in order to accelerate commercialization.
Copyright © 2020. All rights reserved.